Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same Institution


COD: 107-114 Categorie: ,

Carlo Cappelli, Ilenia Pirola, Marco Braga, Elvira De Martino, Maria Laura Morassi, Elena Gandossi, Chiara Mattanza, Rino Balzano, Maurizio Castellano, Enrico Agabiti Rosei

Ann. Ital. Chir., 2006; 77: 107-114

La mia nuova descrizione qui!

Price of a print issue €25.00

AIM: To test the prognostic significant of clinicopathologic factors in patients affected by well-differentiated thyroid carcinoma
METHODS: A retrospective review of patients treated for WDTC (thyroidectomy and a radioactive iodine (I131) thyroid
ablation) at our Institute with a minimum of 10 years of follow-up was carried out. The unfavourable prognosis at the
end of the follow-up was defined as persistence/recurrence of WDTC or death due to the cancer.
RESULTS: 234 patients (162 female, 72 male), mean age of 47.6±16.6 years, were included in this study (mean follow-
up 158.4±34.8 months): 78 (33.4%) subjects had persistence/recurrence of neoplasia while 5 (2.1%) died for cancer.
The multivariate regression showed that prognostic factors were old age, size of cancer, detectable thyroglonulin levels
six months after metabolic ablation, and DeGroot staging system.
DISCUSSION: Our mortality rate is lower (2.1%) than reported in literature (10%): this could be explained by the different
pathological classification and treatment. The mortality rate appears higher in patients treated with emitiroidectomy
and TSH suppressive therapy than in those with total thyroidectomy and I131 ablation. Even if we have chosen
an “aggressive” therapy and our mortality rate is lower, one third of patients have persistence/recurrence of cancer: it
seems that tumour recurrence rate better reflects clinical problems related to cancer.
CONCLUSION: WDTC has with a good disease-specific survival but a significant recurrence rate. The most important
predictors are the old age and the size of lesion. We suggest a radical surgery followed by radiometabolic ablation in all
patients with WDTC.


Utilizzando il sito, accetti l'utilizzo dei cookie da parte nostra. maggiori informazioni

Questo sito utilizza i cookie per fornire la migliore esperienza di navigazione possibile. Continuando a utilizzare questo sito senza modificare le impostazioni dei cookie o cliccando su "Accetta" permetti il loro utilizzo.